Oncology

The Pharmacy Times® Oncology resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

What can we help you find?
[[thumbnail_alt_text]]
These study results were announced by Eisai and Merck during the 2020 American Society of Clinical Oncology Virtual Scientific Program, May 29-31. 
[[thumbnail_alt_text]]
As clinicians, we must first understand the unique challenges that a patient is facing and then tailor our support to address their specific needs. 
[[thumbnail_alt_text]]
Pharmacists can deliver value-based oncology services as an integral part of the health care team to improve patient outcomes. 
[[thumbnail_alt_text]]
Sarcomas account for about 1% of all adult cancers and 15% of all pediatric cancers.
[[thumbnail_alt_text]]
Many pharmacies may be missing significant, profitable opportunities...via generic pharmaceuticals.
[[thumbnail_alt_text]]
The investigators found that patients with preexisting neutropenia could be managed on venetoclax, although use of G-CSF would likely also be required in conjunction with the treatment.
[[thumbnail_alt_text]]
Both premenopausal and postmenopausal breast cancer rates are rising globally. 
[[thumbnail_alt_text]]
Although the treatment of cancer is facing many challenges, the pandemic is also creating massive amounts of new data with which to educate patients, conduct new research, and make more informed clinical decisions.
[[thumbnail_alt_text]]
This Pharmacy Times Webcast provides an overview of how the COVID-19 pandemic has impacted the treatment and management of patients with cancer.
[[thumbnail_alt_text]]
Following initial breast cancer diagnosis by mammography, MRI, or ultrasound, treatment is largely based upon the histologic subtype and staging of the tumor(s).
[[thumbnail_alt_text]]
Data aggregation partners can provide value in their ability to pull clinical information from both the HSSP and electronic health records.
[[thumbnail_alt_text]]
Meaningful breakthrough therapies are receiving accelerated approval based on evidence of impact on a surrogate end point rather than evidence of impact on the actual clinical benefit for which the drug is intended.